The publication by Guler et al. [1] highlights a very problematic area in valvular surgery, the treatment of paravalvular leakage (PVL). They successfully treated mitral PVL transapically in a highrisk patient with an Amplatzer duct occluder device. They avoided all the known complications of redo surgery and the additional risks that might be brought by the comorbidities of the patient. The relation of the PVL with the hinge points of the prosthetic valve was very well emphasized, which is one of the most important determinants of procedural success rates. They also used three-dimensional transoesophageal echocardiography and demonstrated the procedure with excellent pictures.
In this valuable report, there is a particular topic we would like to discuss. We know that mitral PVL has a detrimental course, especially compared with aortic PVL (16 ± 8 vs 70 ± 12% event-free survival rates in 8 years) [2] . This finding mandates immediate therapeutic intervention. In percutenous modalities of PVL occlusion, there is no real rim-like atrial septum. The anatomy may increase the tendency for residual leakages after the first occluder deployment. In addition, this strategy, particularly in the aortic position, may cause a new PVL in the anterior or posterior aspect of the device, which may require a second or third occluder implantation and even embolization after first occluder implantation. Therefore, the size of the connector that connects both discs should be of the same diameter as the defect. Sriratanaviriyakul et al. [3] reported a similar case in which they had to implant a second occluder device. So, it should be emphasized that, due to anatomical features, size matters in occluder device treatment of PVLs to prevent secondary leakages and possible embolization. Because, as the number of implanted occluder devices increase due to unfavorable anatomy, the risk of embolization will also increase. Embolized occluder devices, even in simple secundum atrial septal defects, increase the mortality 20-fold compared with elective surgery [4] .
In conclusion, we believe that interventional treatment modalities of PVL will save patients' lives with decreased adverse event rates. We would like to congratulate the authors for their success and thank them for sharing their experience with the readers. We would like to thank Durukan et al. [1] for their contribution to our paper further elucidating our position on transapical or transfemoral paravalvular leakage closure. Moreover, it is better to explain the procedure in more detail. The Amplatzer duct occluder II (ADO II) is a self-expanding nitinol mesh device specifically designed to occlude a tube connecting two larger chambers, e.g. in patent ductus arteriosus, where the aorta and pulmonary arteries are connected. There are many different families of Amplatzer occluders that used to close different anatomical defects, and each of them has defect-specific technical properties. For example, the Amplatzer septal occluder (ASO) device used to occlude single atrial septal defects has two discs connected by a waist. However, the connection point between waist and both discs is designed in a different manner from the ADO II. The connection between the waist and discs is a cylindrical-shaped continuation with the same diameter as the waist in the ASO, whereas in ADO II, the diameter of the waist gradually decreases and connects to discs with a smaller diameter than the waist [2] . This feature prevents disc deformation and provides conformism for both discs according to the shape of both ends of the paravalvular defect, if a device of appropriate length is chosen, while the waist accommodates the defect.
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The ADO II is available in eight sizes with four waist diameters (3, 4, 5, and 6 mm) and there are two length options for each waist diameter (4 or 6 mm). In our case, [3] the device length was 4 mm and the waist diameter was 6 mm (with a circumference of 18.84 mm). However, the height of the mechanical valve was standard and was 5 mm, and its sewing cuff height was almost 4 mm with the suture and endothelial cover. The paravalvular defect width was 5 mm [3] . Although not mentioned in the article, the lateral diameter was 3 mm, and the circular length 16 mm, which was smaller than the waist circumference of the device. We think that the defect circumference should be a little bit smaller than the waist circumference of the device and the maximum length of the device should be up to the length of the defect. If a device with a larger waist circumference is chosen, it will fit the shape of the paravalvular defect perfectly with the help of its self-expanding property, while its length increases and both discs prevent embolization.
The self-expandability, a slightly larger waist circumference, localized convergence at each disc and appropriate device length allow device fixation and conformism within the paravalvular anatomical defect, provide protection from embolization and prevent the occurrence of new paravalvular leakages under 3D-TEE and fluoroscopic guidance.
